GYRE Fundamental Analysis - GYRE THERAPEUTICS INC

Fundamental Rating

GYRE gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 542 industry peers in the Biotechnology industry. GYRE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. GYRE has a decent growth rate and is not valued too expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

GYRE had positive earnings in the past year.

In the past year GYRE had a positive cash flow from operations.

In the past 5 years GYRE reported 4 times negative net income.

In the past 5 years GYRE reported 4 times negative operating cash flow.

1.2 Ratios

GYRE's Return On Assets of 2.73% is amongst the best of the industry. GYRE outperforms 90.77% of its industry peers.

GYRE has a Return On Equity of 4.53%. This is amongst the best in the industry. GYRE outperforms 91.70% of its industry peers.

With an excellent Return On Invested Capital value of 5.30%, GYRE belongs to the best of the industry, outperforming 92.62% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	2.73%
ROE	4.53%
ROIC	5.3%

ROA(3y)-33.04%

ROA(5y)-63.26%

ROE(3y)-80.93%

ROE(5y)-106.13%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GYRE's Profit Margin of 4.08% is amongst the best of the industry. GYRE outperforms 90.96% of its industry peers.

The Operating Margin of GYRE (9.14%) is better than 91.88% of its industry peers.

With an excellent Gross Margin value of 95.91%, GYRE belongs to the best of the industry, outperforming 94.65% of the companies in the same industry.

		Industry Rank	Sector Rank
OM	9.14%
PM (TTM)	4.08%
GM	95.91%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GYRE has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.

The number of shares outstanding for GYRE has been increased compared to 1 year ago.

GYRE has more shares outstanding than it did 5 years ago.

GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

An Altman-Z score of 7.77 indicates that GYRE is not in any danger for bankruptcy at the moment.

GYRE has a better Altman-Z score (7.77) than 81.92% of its industry peers.

GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	7.77

ROIC/WACC0.54

WACC9.86%

2.3 Liquidity

A Current Ratio of 5.40 indicates that GYRE has no problem at all paying its short term obligations.

GYRE has a Current ratio (5.40) which is in line with its industry peers.

A Quick Ratio of 4.87 indicates that GYRE has no problem at all paying its short term obligations.

GYRE has a Quick ratio of 4.87. This is comparable to the rest of the industry: GYRE outperforms 54.61% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.4
Quick Ratio	4.87

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 104.97%, which is quite impressive.

Looking at the last year, GYRE shows a very negative growth in Revenue. The Revenue has decreased by -38.38% in the last year.

GYRE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 143.34% yearly.

EPS 1Y (TTM)104.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-87.28%

Revenue 1Y (TTM)-38.38%

Revenue growth 3Y143.34%

Revenue growth 5YN/A

Sales Q2Q%6.13%

3.2 Future

Based on estimates for the next years, GYRE will show a very strong growth in Earnings Per Share. The EPS will grow by 77.26% on average per year.

Based on estimates for the next years, GYRE will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.

EPS Next Y-61.14%

EPS Next 2Y94.64%

EPS Next 3Y77.26%

EPS Next 5YN/A

Revenue Next Year4.24%

Revenue Next 2Y40.6%

Revenue Next 3Y43.57%

Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 192.75, which means the current valuation is very expensive for GYRE.

Based on the Price/Earnings ratio, GYRE is valued cheaply inside the industry as 90.04% of the companies are valued more expensively.

When comparing the Price/Earnings ratio of GYRE to the average of the S&P500 Index (26.90), we can say GYRE is valued expensively.

GYRE is valuated cheaply with a Price/Forward Earnings ratio of 6.46.

Based on the Price/Forward Earnings ratio, GYRE is valued cheaper than 98.34% of the companies in the same industry.

GYRE is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.52, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	192.75
Fwd PE	6.46

4.2 Price Multiples

90.22% of the companies in the same industry are more expensive than GYRE, based on the Enterprise Value to EBITDA ratio.

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	54.99

4.3 Compensation for Growth

A more expensive valuation may be justified as GYRE's earnings are expected to grow with 77.26% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y94.64%

EPS Next 3Y77.26%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GYRE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GYRE THERAPEUTICS INC

NASDAQ:GYRE (9/2/2025, 8:08:04 PM)

After market: 7.71 0 (0%)

7.71

-0.03 (-0.39%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-11 2025-08-11/amc

Earnings (Next)11-11 2025-11-11

Inst Owners3.02%

Inst Owner Change30.59%

Ins Owners7.25%

Ins Owner Change2.09%

Market Cap700.30M

Analysts82.86

Price Target20.4 (164.59%)

Short Float %15.2%

Short Ratio14.68

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-18.3%

Min EPS beat(2)-34.64%

Max EPS beat(2)-1.96%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-19.32%

Min Revenue beat(2)-23.85%

Max Revenue beat(2)-14.79%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)66.67%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)-0.74%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-0.79%

Valuation

		Industry Rank	Sector Rank
PE	192.75
Fwd PE	6.46
P/S	6.85
P/FCF	N/A
P/OCF	755.45
P/B	7.61
P/tB	8.04
EV/EBITDA	54.99

EPS(TTM)0.04

EY0.52%

EPS(NY)1.19

Fwd EY15.48%

FCF(TTM)-0.02

FCFYN/A

OCF(TTM)0.01

OCFY0.13%

SpS1.13

BVpS1.01

TBVpS0.96

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	2.73%
ROE	4.53%
ROCE	6.88%
ROIC	5.3%
ROICexc	8.85%
ROICexgc	9.42%
OM	9.14%
PM (TTM)	4.08%
GM	95.91%
FCFM	N/A

ROA(3y)-33.04%

ROA(5y)-63.26%

ROE(3y)-80.93%

ROE(5y)-106.13%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.67

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	0
Cap/Depr	122.05%
Cap/Sales	2.49%
Interest Coverage	250
Cash Conversion	8.12%
Profit Quality	N/A
Current Ratio	5.4
Quick Ratio	4.87
Altman-Z	7.77

F-Score5

WACC9.86%

ROIC/WACC0.54

Cap/Depr(3y)333.79%

Cap/Depr(5y)313.61%

Cap/Sales(3y)3.51%

Cap/Sales(5y)4.57%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)104.97%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-87.28%

EPS Next Y-61.14%

EPS Next 2Y94.64%

EPS Next 3Y77.26%

EPS Next 5YN/A

Revenue 1Y (TTM)-38.38%

Revenue growth 3Y143.34%

Revenue growth 5YN/A

Sales Q2Q%6.13%

Revenue Next Year4.24%

Revenue Next 2Y40.6%

Revenue Next 3Y43.57%

Revenue Next 5Y-14.87%

EBIT growth 1Y-75.19%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y90.78%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y105.3%

OCF growth 3YN/A

OCF growth 5YN/A

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens